| Filed On | Filing |
|---|---|
| 03 Mar 2025 | TOTAL VOTING RIGHTS |
| 28 Feb 2025 | HOLDING(S) IN COMPANY |
| 28 Feb 2025 | DIRECTOR/PDMR SHAREHOLDING |
| 28 Feb 2025 | DIRECTOR/PDMR SHAREHOLDING |
| 27 Feb 2025 | JOSEPH CIAFFONI APPOINTED CHIEF EXECUTIVE OFFICER |
| 27 Feb 2025 | DIRECTOR/PDMR SHAREHOLDING |
| 27 Feb 2025 | DIRECTOR/PDMR SHAREHOLDING |
| 25 Feb 2025 | HOLDING(S) IN COMPANY |
| 24 Feb 2025 | FDA APPROVAL OF SUBLOCADE LABEL CHANGES |
| 20 Feb 2025 | 6-K |
| 12 Feb 2025 | DELAYED FDA APPROVAL OF SUBLOCADE LABEL CHANGES |
| 04 Feb 2025 | COMPLETION OF SHARE REPURCHASE PROGRAM |
| 04 Feb 2025 | NOTICE OF RESULTS |
| 04 Feb 2025 | TRANSACTION IN OWN SHARES |
| 03 Feb 2025 | APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR |
| 03 Feb 2025 | TOTAL VOTING RIGHTS |
| 28 Jan 2025 | TRANSACTION IN OWN SHARES |
| 28 Jan 2025 | HOLDING(S) IN COMPANY |
| 28 Jan 2025 | DR. DAVID WHEADON APPOINTED CHAIR OF THE BOARD |
| 27 Jan 2025 | HOLDING(S) IN COMPANY |
Loading...
